Search Results - "FIJNVANDRAAT, K."

The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH by Makris, M., Oldenburg, J., Mauser‐Bunschoten, E. P., Peerlinck, K., Castaman, G., Fijnvandraat, K.

Get full text

Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play? by Hazendonk, H.C.A.M., van Moort, I., Mathôt, R.A.A., Fijnvandraat, K., Leebeek, F.W.G., Collins, P.W., Cnossen, M.H.

“…Replacement therapy with clotting factor concentrates (CFC) is the mainstay of treatment in hemophilia. Its widespread application has led to a dramatic…”
Get full text

A high rate of post thrombotic complication in pediatric portal vein thrombosis by Vrijburg, M., Sari, S., Koot, B.G.P., Fijnvandraat, K., Klaassen, ILM

“…Portal vein thrombosis (PVT) is a rare disease in children and may be complicated by portal hypertension (PH), hepatopulmonary syndrome (HPS) and…”
Get full text

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A- A Systematic Review and Meta-Analysis by Abdi, A, Bordbar, M R, Hassan, S, Rosendaal, F R, van der Bom, J G, Voorberg, J, Fijnvandraat, K, Gouw, S C

“…In hemophilia A the presence of non-neutralizing antibodies (NNAs) against Factor VIII (FVIII) may predict the development of neutralizing antibodies…”
Get full text

Clinically relevant differences between assays for von Willebrand factor activity by Boender, J., Eikenboom, J., Bom, J. G., Meijer, K., Meris, J., Fijnvandraat, K., Cnossen, M. H., Laros‐van Gorkom, B. A. P., Heerde, W. L., Mauser‐Bunschoten, E. P., Maat, M. P. M., Leebeek, F. W. G.

“…Essentials It is unclear whether there are differences between von Willebrand factor (VWF) activity assays. We compared the four most used VWF activity assays…”
Get full text

Early-Onset Thrombocytopenia in Small-For-Gestational-Age Neonates: A Retrospective Cohort Study by Fustolo-Gunnink, S F, Vlug, R D, Smits-Wintjens, V E H J, Heckman, E J, Te Pas, A B, Fijnvandraat, K, Lopriore, E

“…Thrombocytopenia is a common finding in small for gestational age (SGA) neonates and is thought to result from a unique pathophysiologic mechanism related to…”
Get full text

Mortality caused by intracranial bleeding in non‐severe hemophilia A patients: reply by Loomans, J. I., Fijnvandraat, K.

Get full text

Intensity of factor VIII treatment and the development of inhibitors in non‐severe hemophilia A patients: results of the INSIGHT case–control study by Velzen, A. S., Eckhardt, C. L., Peters, M., Leebeek, F. W. G., Escuriola‐Ettingshausen, C., Hermans, C., Keenan, R., Astermark, J., Male, C., Peerlinck, K., Cessie, S., Bom, J. G., Fijnvandraat, K.

“…Essentials Research suggests that intensive treatment episodes may increase the risk to develop inhibitors. We performed an international nested case‐control…”
Get full text

Are thrombocytopenia and platelet transfusions associated with major bleeding in preterm neonates? A systematic review by Fustolo-Gunnink, S.F., Huisman, E.J., van der Bom, J.G., van Hout, F.M.A., Makineli, S., Lopriore, E., Fijnvandraat, K.

“…Over 75% of severely thrombocytopenic preterm neonates receive platelet transfusions to prevent bleeding, but transfusion guidelines are based mainly on expert…”
Get full text

CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease by Sanders, Y. V., Bom, J. G., Isaacs, A., Cnossen, M. H., Maat, M. P. M., Laros‐van Gorkom, B. A. P., Fijnvandraat, K., Meijer, K., Duijn, C. M., Mauser‐Bunschoten, E. P., Eikenboom, J., Leebeek, F. W. G., Coppens, M., Kors, A., Meris, J., Nijziel, M. R., Tamminga, R. Y. J., Ypma, P. F., Smiers, F. J. W., Granzen, B., Hamulyák, K., Brons, P.

“…Summary Background von Willebrand factor (VWF) levels in healthy individuals are influenced by variations in genetic loci other than the VWF gene, whose…”
Get full text

Inhibitors - genetic and environmental factors by Lillicrap, D., Fijnvandraat, K., Santagostino, E.

“…Summary It is known that a large number of both genetic and environmental factors contribute to the risk of inhibitor development, but underlying pathogenetic…”
Get full text

von Willebrand disease and aging: an evolving phenotype by Sanders, Y. V., Giezenaar, M. A., Laros‐van Gorkom, B. A. P., Meijer, K., Bom, J. G., Cnossen, M. H., Nijziel, M. R., Ypma, P. F., Fijnvandraat, K., Eikenboom, J., Mauser‐Bunschoten, E. P., Leebeek, F. W. G.

“…Summary Background Because the number of elderly von Willebrand disease (VWD) patients is increasing, the pathophysiology of aging in VWD has become…”
Get full text

5613354 SCREENING FOR CEREBROVASCULAR DISEASE IN CHILDREN WITH SICKLE CELL DISEASE USING TRANSCRANIAL DOPPLER AND MRA TO PREVENT STROKE: THE AMSTERDAM COHORT by Ligt, L.A., Eckhardt, C.L., Fijnvandraat, K., Heijboer, H.

Get full text

Major differences in clinical presentation, diagnosis and management of men and women with autosomal inherited bleeding disorders by Atiq, F., Saes, J.L., Punt, M.C., van Galen, K.P.M., Schutgens, R.E.G., Meijer, K., Cnossen, M.H., Laros-Van Gorkom, B.A.P., Peters, M., Nieuwenhuizen, L., Kruip, M.J.H.A., de Meris, J., van der Bom, J.G., van der Meer, F.J.M., Fijnvandraat, K., Kruis, I.C., van Heerde, W.L., Eikenboom, H.C.J., Leebeek, Frank W.G., Schols, S.E.M.

“…In recent years, more awareness is raised about sex-specific dilemmas in inherited bleeding disorders. However, no large studies have been performed to assess…”
Get full text

Are low-molecular-weight heparins safe and effective in children? A systematic review by Klaassen, Irene L.M., Sol, Jeanine J., Suijker, Monique H., Fijnvandraat, K., van de Wetering, Marianne D., Heleen van Ommen, C.

“…The incidence of venous thromboembolism (VTE) in children is rising. Hence, there is an increasing off-label use of low-molecular-weight heparin (LMWH). There…”
Get full text

Intensive peri‐operative use of factor VIII and the Arg593→Cys mutation are risk factors for inhibitor development in mild/moderate hemophilia A by ECKHARDT, C.L., MENKE, L.A., VAN OMMEN, C.H., VAN DER LEE, J.H., GESKUS, R.B., KAMPHUISEN, P.W., PETERS, M., FIJNVANDRAAT, K.

“…Background: A severe and challenging complication in the treatment of hemophilia A is the development of inhibiting antibodies (inhibitors) directed towards…”
Get full text

In silico evaluation of limited sampling strategies for individualized dosing of extended half-life factor IX concentrates in hemophilia B patients by Preijers, T., van Spengler, M. W. F., Meijer, K., Fijnvandraat, K., Fischer, K., Leebeek, F. W. G., Cnossen, M. H., Mathôt, R. A. A.

“…Purpose Hemophilia B is a bleeding disorder, caused by a factor IX (FIX) deficiency. Recently, FIX concentrates with extended half-life (EHL) have become…”
Get full text

In Vivo T1 of Blood Measurements in Children with Sickle Cell Disease Improve Cerebral Blood Flow Quantification from Arterial Spin-Labeling MRI by Václavů, L, van der Land, V, Heijtel, D F R, van Osch, M J P, Cnossen, M H, Majoie, C B L M, Bush, A, Wood, J C, Fijnvandraat, K J, Mutsaerts, H J M M, Nederveen, A J

“…Children with sickle cell disease have low hematocrit and elevated CBF, the latter of which can be assessed with arterial spin-labeling MR imaging…”
Get full text

Male gender, school attendance and sports participation are positively associated with health‐related quality of life in children and adolescents with congenital bleeding disorders by Limperg, P. F., Joosten, M. M. H., Fijnvandraat, K., Peters, M., Grootenhuis, M. A., Haverman, L.

“…Background This study assesses health‐related quality of life (HRQOL), and variables associated with HRQOL, in children and adolescents with haemophilia and…”
Get full text

Measuring anxiety and depression in young adult men with haemophilia using PROMIS by Heesterbeek, M.R., Luijten, M.A.J., Gouw, S.C., Limperg, P.F., Fijnvandraat, K., Coppens, M., Kruip, M.J.H.A., Eikenboom, J., Grootenhuis, M.A., Flens, G., Terwee, C.B., Peters, M., Haverman, L.

Get full text